Neuland Laboratories Limited

Neuland Laboratories Limited

Neuland Laboratories Limited has received an Establishment Inspection Report (EIR) from the US FDA following an inspection at its Unit 3 manufacturing facility, which has been concluded as 'closed'.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding the closure of the trading window for dealing in the company's equity shares from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026.

Neuland Laboratories Limited

Neuland Laboratories Limited has intimated the schedule of analyst/institutional investor meetings to be held on September 23-25, 2026, in Singapore, as part of the Goldman Sachs Global Healthcare CDMO Day and one-on-one meetings.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Press Release". The content of the press release is not specified.

Neuland Laboratories Limited

Neuland Laboratories Limited has announced its schedule for analyst/institutional investor meetings on September 15 and 17, 2026, in Hyderabad. The meetings are subject to change due to any exigencies.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations' for the purchase of approximately 134 acres of land for future expansion.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Crisil Ratings reaffirming the company's credit rating as CRISIL A+/ Positive with a revised outlook to 'Positive' and reaffirming the short-term rating as CRISIL A1.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding Special Window for transfer and dematerialization of physical shares.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding 'Intimation Regarding Completion Of US FDA Inspection'. The US FDA inspected the company's Unit 3 manufacturing facility from 10th to 14th of August 2026 and issued a Form 483 with one observation related to procedural improvements in water and environmental monitoring.

Neuland Laboratories Limited

Neuland Laboratories Limited's Q1FY27 earnings conference call transcript is available on their website, with CEO Saharsh Davuluri, CFO Abhijit Majumdar, and Head of Corporate Planning and Strategy Sajeev Medikonda discussing the company's financial performance, working capital efficiency, and capital expenditure.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about its schedule of analyst/institutional investor meetings, including a group meet and one-on-one meetings on August 12, 2026, at Emkay Confluence 2026 in Mumbai.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding financial results for the quarter ended June 30, 2026.

Neuland Laboratories Limited

Neuland Laboratories Limited has made available the audio recording of its earnings call for the quarter ended June 30, 2026, conducted on August 5, 2026, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Neuland Laboratories Limited

Neuland Laboratories Limited has announced the enhancement of its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The existing capacity of 376.5 KL will be increased by 18 KL, with an investment of Rs. 39.8 crores (including GST) to be completed within 6-7 months. The company has also approved the execution of a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for a loan licence agreement to establish dedicated manufacturing capacity and incur capital expenditure.

Neuland Laboratories Limited

Neuland Laboratories Limited has disclosed that it will be executing a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited, as part of a loan licence agreement to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The company has also announced plans to enhance its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana, with a proposed capacity addition of 18 KL and an investment of Rs. 39.8 crores.

Neuland Laboratories Limited

Neuland Laboratories Limited has presented its Q1FY27 financial results, showing a 116.3% YoY increase in total income to Rs. 650.1 crore, with EBITDA margin increasing by 2150 bps YoY to 35.5%. The company's net debt stood at Rs. (308.5) crore as at Q1FY27 end.

Neuland Laboratories Limited

Neuland Laboratories Limited has announced its Q1FY27 financial results, with total income at Rs.650.1 crore and EBITDA at Rs.231.1 crore, representing a 116.3% and 448.2% YoY increase respectively.

Neuland Laboratories Limited

Neuland Laboratories Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, and announced the execution of a corporate guarantee of Rs. 40 crores in favor of Gland Pharma Limited. The company also enhanced its manufacturing capacity at Unit 1.

Neuland Laboratories Limited

Neuland Laboratories Limited held its 42nd Annual General Meeting on August 4, 2026, through video conferencing, with 81 members attending. The meeting approved the audited financial statements, final dividend of Rs. 34.00 per equity share, and other resolutions.